Vice Provost and Dean of Research
Showing 751-800 of 2,458 Results
-
Anna L Gloyn
Professor of Pediatrics (Endocrinology) and of Genetics
Current Research and Scholarly InterestsAnna's current research projects are focused on the translation of genetic association signals for type 2 diabetes and glycaemic traits into cellular and molecular mechanisms for beta-cell dysfunction and diabetes. Her group uses a variety of complementary approaches, including human genetics, functional genomics, physiology and islet-biology to dissect out the molecular mechanisms driving disease pathogenesis.
-
Ashish Goel
Stanford W. Ascherman, MD Professor in the School of Engineering and Professor, by courtesy, of Computer Science
BioAshish Goel is a Professor of Management Science and Engineering, the Fortinet Founders Chair of Management Science and Engineering, and Professor (by courtesy) of Computer Science at Stanford University. He received his PhD in Computer Science from Stanford in 1999, and was an Assistant Professor of Computer Science at the University of Southern California from 1999 to 2002. His research interests lie in the design, analysis, and applications of algorithms.
-
Lauren Goins
Assistant Professor of Developmental Biology
Current Research and Scholarly InterestsThe Goins lab aims to understand how cells make decisions. Our research focuses on how young, immature blood stem cells, with the potential to become many different cell types, choose between these cell fates.
-
Garry Gold
Stanford Medicine Professor of Radiology and Biomedical Imaging
On Leave from 02/16/2026Current Research and Scholarly InterestsMy primary focus is application of new MR imaging technology to musculoskeletal problems. Current projects include: Rapid MRI for Osteoarthritis, Weight-bearing cartilage imaging with MRI, and MRI-based models of muscle. We are studying the application of new MR imaging techniques such as rapid imaging, real-time imaging, and short echo time imaging to learn more about biomechanics and pathology of bones and joints. I am also interested in functional imaging approaches using PET-MRI.
-
Jeffrey Goldberg, MD, PhD
Blumenkranz Smead Professor
Current Research and Scholarly InterestsLab research on molecular mechanisms of survival and regeneration in the visual system; retinal development and stem cell biology; nanoparticles and tissue engineering. Clinical trials in imaging, biomarker development, and neuroprotection and vision restoration in glaucoma and other neurodegenerative diseases.
-
Jeremy Goldbogen
Associate Professor of Oceans
BioJeremy Goldbogen is an Associate Professor of Oceans at Stanford University, based at the Hopkins Marine Station in Pacific Grove, California. He is a comparative physiologist who studies the integrative biology of marine organisms, with a particular focus on the feeding biomechanics, energetics, and foraging ecology of baleen whales.
Goldbogen received his B.S. in Zoology from the University of Texas at Austin, where he began his research career studying the biomechanics of locomotion in hummingbirds and Antarctic pteropods. He earned his M.S. in Marine Biology from Scripps Institution of Oceanography and his Ph.D. in Zoology from the University of British Columbia, where his dissertation on the mechanics and energetics of rorqual lunge feeding earned him the Governor General's Gold Medal—UBC's most outstanding PhD award. Following postdoctoral positions at Scripps and the Cascadia Research Collective, he joined Stanford's faculty in 2014.
His research program uses cutting-edge bio-logging technology—animal-attached sensors including accelerometers, video cameras, and echosounders—to study the behavior and physiology of marine megafauna in their natural environment. His lab has made groundbreaking discoveries about whale feeding mechanics, cardiovascular function, and the ecological consequences of body size in cetaceans. Notable achievements include the first recordings of a blue whale's heart rate and insights into why whales are big but not bigger. -
Jeremy Goldhaber-Fiebert
Professor of Health Policy
BioJeremy Goldhaber-Fiebert, PhD, is a Professor of Health Policy and a Core Faculty Member in the Centers for Health Policy and Primary Care and Outcomes Research. His research focuses on complex policy decisions surrounding the prevention and management of increasingly common, chronic diseases and the life course impact of exposure to their risk factors. In the context of both developing and developed countries including the US, India, China, and South Africa, he has examined chronic conditions including type 2 diabetes and cardiovascular diseases, human papillomavirus and cervical cancer, tuberculosis, and hepatitis C and on risk factors including smoking, physical activity, obesity, malnutrition, and other diseases themselves. He combines simulation modeling methods and cost-effectiveness analyses with econometric approaches and behavioral economic studies to address these issues. Dr. Goldhaber-Fiebert graduated magna cum laude from Harvard College in 1997, with an A.B. in the History and Literature of America. After working as a software engineer and consultant, he conducted a year-long public health research program in Costa Rica with his wife in 2001. Winner of the Lee B. Lusted Prize for Outstanding Student Research from the Society for Medical Decision Making in 2006 and in 2008, he completed his PhD in Health Policy concentrating in Decision Science at Harvard University in 2008. He was elected as a Trustee of the Society for Medical Decision Making in 2011 and Secretary/Treasurer in 2021.
Past and current research topics:
- Type 2 diabetes and cardiovascular risk factors: Randomized and observational studies in Costa Rica examining the impact of community-based lifestyle interventions and the relationship of gender, risk factors, and care utilization.
-Cervical cancer: Model-based cost-effectiveness analyses and costing methods studies that examine policy issues relating to cervical cancer screening and human papillomavirus vaccination in countries including the United States, Brazil, India, Kenya, Peru, South Africa, Tanzania, and Thailand.
- Measles, haemophilus influenzae type b, and other childhood infectious diseases: Longitudinal regression analyses of country-level data from middle and upper income countries that examine the link between vaccination, sustained reductions in mortality, and evidence of herd immunity.
- Patient adherence: Studies in both developing and developed countries of the costs and effectiveness of measures to increase successful adherence. Adherence to cervical cancer screening as well as to disease management programs targeting depression and obesity is examined from both a decision-analytic and a behavioral economics perspective.
- Simulation modeling methods: Research examining model calibration and validation, the appropriate representation of uncertainty in projected outcomes, the use of models to examine plausible counterfactuals at the biological and epidemiological level, and the reflection of population and spatial heterogeneity. -
David Goldhaber-Gordon
TG Wijaya Professor of Physics and Professor, by courtesy, of Applied Physics
Current Research and Scholarly InterestsHow do electrons organize themselves on the nanoscale?
We know that electrons are charged particles, and hence repel each other; yet in common metals like copper billions of electrons have plenty of room to maneuver and seem to move independently, taking no notice of each other. Professor Goldhaber-Gordon studies how electrons behave when they are instead confined to tiny structures, such as wires only tens of atoms wide. When constrained this way, electrons cannot easily avoid each other, and interactions strongly affect their organization and flow. The Goldhaber-Gordon group uses advanced fabrication techniques to confine electrons to semiconductor nanostructures, to extend our understanding of quantum mechanics to interacting particles, and to provide the basic science that will shape possible designs for future transistors and energy conversion technologies. The Goldhaber-Gordon group makes measurements using cryogenics, precision electrical measurements, and novel scanning probe techniques that allow direct spatial mapping of electron organization and flow. For some of their measurements of exotic quantum states, they cool electrons to a fiftieth of a degree above absolute zero, the world record for electrons in semiconductor nanostructures. -
Andrea Goldsmith
Stephen Harris Professor in the School of Engineering, Emerita
BioAndrea Goldsmith is the Dean of Engineering and Applied Science and the Arthur LeGrand Doty Professor of Electrical and Computer Engineering at Princeton University. She was previously the Stephen Harris Professor of Engineering and Professor of Electrical Engineering at Stanford University, where she is now Harris Professor Emerita. Her research interests are in information theory, communication theory, and signal processing, and their application to wireless communications, interconnected systems, and biomedical devices. She founded and served as Chief Technical Officer of Plume WiFi (formerly Accelera, Inc.) and of Quantenna (QTNA), Inc, and she serves on the Board of Directors for Intel (INTC), Medtronic (MDT), Crown Castle Inc (CCI), and the Marconi Society. She also serves on the Presidential Council of Advisors on Science and Technology (PCAST). Dr. Goldsmith is a member of the National Academy of Engineering, the Royal Academy of Engineering, and the American Academy of Arts and Sciences. She is a Fellow of the IEEE and has received several awards for her work, including the Marconi Prize, the ACM Sigmobile Outstanding Contribution Award, the IEEE Sumner Technical Field Award, the ACM Athena Lecturer Award, the ComSoc Armstrong Technical Achievement Award, the Kirchmayer Graduate Teaching Award, the WICE Mentoring Award, and the Silicon Valley/San Jose Business Journal’s Women of Influence Award. She is author of the book ``Wireless Communications'' and co-author of the books ``MIMO Wireless Communications,” “Principles of Cognitive Radio,” and “Machine Learning and Wireless Communications,” all published by Cambridge University Press, as well as an inventor on 29 patents. She received the B.S., M.S. and Ph.D. degrees in Electrical Engineering from U.C. Berkeley.
Dr. Goldsmith is the founding Chair of the IEEE Board of Directors Committee on Diversity and Inclusion. She served as President of the IEEE Information Theory Society in 2009, as founding Chair of its Student Committee, and as founding Editor-in-Chief of the IEEE Journal on Selected Areas in Information Theory. She has also served on the Board of Governors for both the IEEE Information Theory and Communications Societies. At Stanford she served as Chair of Stanford’s Faculty Senate and for multiple terms as a Senator, and on its Academic Council Advisory Board, Budget Group, Committee on Research, Planning and Policy Board, Commissions on Graduate and on Undergraduate Education, Faculty Women’s Forum Steering Committee, and Task Force on Women and Leadership. -
Judith L. Goldstein
Janet M. Peck Professor of International Communication, Professor of Political Science and Senior Fellow at the Stanford Institute for Economic Policy Research
BioJudith L. Goldstein is the Janet M. Peck Professor of International Communication and the Kaye University Fellow in Undergraduate Education. Her research focuses on international political economy, with a focus on trade politics. She has written and/or edited six book including Ideas, Interests and American Trade Policy and more recently The Evolution of the Trade Regime: Politics, Law and Economics of the GATT and the WTO. Her articles have appeared in numerous journals.
Her current research focuses on the political requisites for trade liberalization focusing both on tariff bargaining and public preferences. As well, she is engaged in the analysis of a large survey panel, which focuses on how economic hard times influences public opinion.
Goldstein has a BA from the University of California Berkeley, a Masters degree from Columbia University and a Ph.D. from UCLA. -
Mary Kane Goldstein
Professor of Health Policy, Emerita
Current Research and Scholarly InterestsHealth services research in primary care and geriatrics: developing, implementing, and evaluating methods for clinical quality improvement. Current work includes applying health information technology to quality improvement through clinical decision support (CDS) integrated with electronic health records; encoding clinical knowledge into computable formats in automated knowledge bases; natural language processing of free text in electronic health records; analyzing multiple comorbidities
-
Andrea Goldstein-Piekarski
Assistant Professor (Research) of Psychiatry and Behavioral Sciences (Sleep Medicine)
BioDr. Goldstein-Piekarski directs the Computational Psychiatry, Neuroscience, and Sleep Laboratory (CoPsyN Sleep Lab) as an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine and PI within the Sierra-Pacific Mental Illness Research, Education and Clinical Center (MIRECC) at the Palo Alto VA. She received her PhD in 2014 at the University of California, Berkeley where she studied the consequences of sleep on emotional brain function. She then completed a Postdoctoral fellowship at Stanford focusing on understanding the brain basis of anxiety and depression.
As the director of the CoPsyN Sleep Lab she is developing a translational, interdisciplinary research program that combines human neuroimaging, high-density EEG sleep recording, and computational modeling to understand the neural mechanisms through which sleep disruption contributes to affective disorders, particularly depression, across the lifespan. The ultimate goals of this research are to (1) develop mechanistically-informed interventions that directly target aspects of sleep and brain function to prevent and treat affective disorders and (2) identify novel biomarkers which can identify which individuals are most likely to experience improved mood following targeted sleep interventions.
This work is currently supported by The KLS Foundation, a R01 from National Institute of Mental Health, and a R61 from the National Institute of Mental Health. -
Natalia Gomez-Ospina
Assistant Professor of Pediatrics (Genetics)
Current Research and Scholarly InterestsDr. Gomez-Ospina is a physician scientist and medical geneticist with a strong interest in the diagnosis and management of genetic diseases.
1) Lysosomal storage diseases:
Her research program is on developing better therapies for a large class of neurodegenerative diseases in children known as lysosomal storage disorders. Her current focus is on developing genome editing of hematopoietic stem cells as a therapeutic approach for these diseases beginning with Mucopolysaccharidosis type 1 and Gaucher disease. She established a genetic approach where therapeutic proteins can be targeted to a single well-characterized place in the genome known as a safe harbor. This approach constitutes a flexible, “one size fits all” approach that is independent of specific genes and mutations. This strategy, in which the hematopoietic system is commandeered to express and deliver therapeutic proteins to the brain can potentially change the current approaches to treating childhood neurodegenerative diseases and pave the way for alternative therapies for adult neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease
2) Point of care ammonia testing
She also works in collaboration with other researchers at Stanford to develop point-of-care testing for serum ammonia levels. Such device will greatly improve the quality of life of children and families with metabolic disorders with hyperammonemia.
3) Gene discovery
Dr Gomez-Ospina lead a multi-institutional collaboration resulting in the discovery of a novel genetic cause of neonatal and infantile cholestatic liver disease. She collaborated in the description of two novel neurologic syndromes caused by mutations in DYRK1 and CHD4.
For more information go to our website:
https://www.gomezospina.com/ -
Alexander Gonzalez
Scientific Project Manager
Current Role at StanfordScientific Project Manager for the Wu Tsai Human Performance Alliance
-
Benjamin Good
Assistant Professor of Applied Physics and, by courtesy, of Biology
BioBenjamin Good is a theoretical biophysicist with a background in experimental evolution and population genetics. He is interested in the short-term evolutionary dynamics that emerge in rapidly evolving microbial populations like the gut microbiome. Technological advances are revolutionizing our ability to peer into these evolving ecosystems, providing us with an increasingly detailed catalog of their component species, genes, and pathways. Yet a vast gap still remains in understanding the population-level processes that control their emergent structure and function. Our group uses tools from statistical physics, population genetics, and computational biology to understand how microscopic growth processes and genome dynamics at the single cell level give rise to the collective behaviors that can be observed at the population level. Projects range from basic theoretical investigations of non-equilibrium processes in microbial evolution and ecology, to the development of new computational tools for measuring these processes in situ in both natural and experimental microbial communities. Through these specific examples, we seek to uncover unifying theoretical principles that could help us understand, forecast, and eventually control the ecological and evolutionary dynamics that take place in these diverse scenarios.
-
Zinaida Good, Ph.D.
Assistant Professor of Medicine (Immunology and Rheumatology)
Current Research and Scholarly InterestsOur laboratory integrates cutting-edge synthetic biology, immunology, and machine learning to engineer T cell therapies for cancer and autoimmune diseases. We have 3 research areas:
- Analysis of clinical single-cell and spatial transcriptomics datasets from T cell therapy trials to identify mechanisms of resistance
- Building AI systems to generate T cell designs predicted to improve patient outcomes
- Genetic screens of novel T cell designs in models that mimic key mechanisms of resistance -
Miriam B. Goodman
Mrs. George A. Winzer Professor of Cell Biology
Current Research and Scholarly InterestsWe study the molecular events that give rise to the sensation of touch and chemical stressors that compromise touch sensation in C. elegans. To do this, we use a combination of quantitative behavioral analysis, genetics, in vivo electrophysiology, and heterologous expression of ion channels. We collaborate with physicists and other physiologist to expand our experimental research.
-
Stuart Goodman, MD, PhD
The Robert L. and Mary Ellenburg Professor of Surgery and Professor, by courtesy, of Bioengineering
Current Research and Scholarly InterestsAs an academic orthopaedic surgeon, my interests center on adult reconstructive surgery, arthritis surgery, joint replacement, biomaterials, biocompatibility, tissue engineering, mesenchymal stem cells. Collaborative clinical, applied and basic research studies are ongoing.
-
Kenneth Goodson
Vice Provost for Graduate Education and Postdoctoral Affairs, Davies Family Provostial Professor, and Professor, by courtesy, of Materials Science and Engineering
Current Research and Scholarly InterestsProf. Goodson’s Nanoheat Lab studies heat transfer in electronic nanostructures, microfluidic heat sinks, and packaging, focussing on basic transport physics and practical impact for industry. We work closely with companies on novel cooling and packaging strategies for power devices, portables, ASICs, & data centers. At present, sponsors and collaborators include ARPA-E, the NSF POETS Center, SRC ASCENT, Google, Intel, Toyota, Ford, among others.
-
William Rowland Goodyer, MD/PhD
Assistant Professor of Pediatrics (Cardiology)
BioDr. Goodyer is a physician scientist who specializes in Pediatric Cardiology and Electrophysiology. Will graduated from McGill University (Montreal, Canada) with a BSc in Biology prior to completing his graduate studies at Stanford University in the Medical Scientist Training Program (MSTP). He subsequently completed residency training in Pediatrics at Boston Children’s Hospital before returning to Stanford to complete a fellowship in Pediatric Cardiology and advanced fellowship in Pediatric Electrophysiology. He additionally performed a postdoctoral fellowship in the Sean Wu laboratory at the Stanford Cardiovascular Institute where he developed the first comprehensive single-cell gene atlas of the entire murine cardiac conduction system (CCS) as well as pioneered the generation of optical imaging agents for the real-time visualization of the CCS to help prevent accidental surgical damage during heart surgeries. Will's lab (www.goodyerlab.com) focuses on basic science advances aimed at the improved diagnosis and treatment of cardiac arrhythmias.
-
Deborah M Gordon
Paul S. and Billie Achilles Professor of Environmental Biology
Current Research and Scholarly InterestsProfessor Deborah M Gordon studies the evolutionary ecology of collective behavior. Ant colonies operate without central control, using local interactions to regulate colony behavior.
-
Jorg Goronzy
Professor of Medicine (Immunology and Rheumatology), Emeritus
Current Research and Scholarly InterestsT cell homeostasis and function with age
-
Jonathan D. Gortat
Director for Licensing and Strategic Alliances, Office of Technology Licensing (OTL)
BioJonathan Gortat is the Director of Licensing and Strategic Alliances at Stanford University's Office of Technology Licensing with more than 15 years experience in technology transfer. Prior to joining Stanford, he was assistant director at the University of Illinois-Chicago Office of Technology Management and in various roles at Purdue Research Foundation in technology transfer and working on a pre-seed investment fund. In addition, he has more than 5 years industrial pharmacy research and project management experience. He has extensive experience in pharmaceutical and chemical unit operations and analytical methods associated with the pharmaceutical industry. He holds an MBA from the Krannert Graduate School of Management at Purdue University and a baccalaureate of science degree in Chemical Engineering from Purdue University.
-
Ian Gotlib
Marjorie Mhoon Fair Professor
Current Research and Scholarly InterestsCurrent interests include social, cognitive, and biological factors in affective disorders; neural and cognitive processing of emotional stimuli and reward by depressed persons; behavioral activation and anhedonia in depression; social, emotional, and biological risk factors for depression in children.
-
Or Gozani
Dr. Morris Herzstein Professor
Current Research and Scholarly InterestsWe study the molecular mechanisms by which chromatin-signaling networks effect nuclear and epigenetic programs, and how dysregulation of these pathways leads to disease. Our work centers on the biology of lysine methylation, a principal chromatin-regulatory mechanism that directs epigenetic processes. We study how lysine methylation events are generated, sensed, and transduced, and how these chemical marks integrate with other nuclear signaling systems to govern diverse cellular functions.
-
Dita Gratzinger
Professor of Pathology
Current Research and Scholarly InterestsI have research interests in the interaction of normal and neoplastic hematolymphoid cells with the bone marrow. lymph node and spleen microenvironment and the interactions of these compartments with immune perturbation and dysregulation.
-
Edward Graves
Professor of Radiation Oncology (Radiation Physics), and by courtesy, of Radiology
Current Research and Scholarly InterestsApplications of molecular imaging in radiation therapy, small animal image-guided conformal radiotherapy, immune responses to radiation, immunotherapy and radiotherapy combinations, image processing and analysis.
-
Dyneisha Gray
Hit Program Administrator, Office of Technology Licensing (OTL)
Staff, Stanford Office of Technology LicensingBioDyneisha holds a B.S. in Business Administration from California State University Bakersfield. Dyneisha brings administrative experience from her previous roles as an Executive Assistant and Operations Manager for Viva Superheroes where she coordinated company events and managed calendars.
-
Nathanael S. Gray
Krishnan-Shah Family Professor
BioNathanael Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance.
Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. During his six year stay at GNF, Dr. Gray became the director of biological chemistry where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs. Some of the notable accomplishments of Dr. Gray’s team at GNF include: discovery of the first allosteric inhibitors of wild-type and mutant forms of BCR-ABL which resulted in clinical development of ABL001; discovery of the first selective inhibitors of the Anaplastic Lymphoma Kinase (ALK), an achievement that led to the development of now FDA-approved drugs such as ceritinib (LDK378) for the treatment of EML4-ALK expressing non-small cell lung cancer (NSCLC); and discovery that sphingosine-1-phosphate receptor-1 (S1P1) is the pharmacologically relevant target of the immunosuppressant drug Fingomilod (FTY720) followed by the development of Siponimod (BAF312), which is currently used for the treatment of multiple sclerosis.
In 2006, Dr. Gray returned to academia as a faculty member at the Dana Farber Cancer Institute and Harvard Medical School in Boston. There, he has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Dr. Gray’s team developed covalent inhibitors of the T790M mutant of EGFR inspired the development of Osimertinib (AZD9291), now FDA approved for treatment of patients with relapsed lung cancer due to resistance to first generation EGFR inhibitors. Dr. Gray has also developed structure-based, generalized approaches for designing drugs to overcome one of the most common mechanisms of resistance observed against most kinase inhibitor drugs, mutation of the so-called "gatekeeper" residue, which has been observed in resistance to drugs targeting BCR-ABL, c-KIT and PDGFR.
In 2021, Dr. Gray joined Stanford University where he has joined the Stanford Cancer Institute, Chem-H and the Innovative Medicines Accelerator (IMA) to spur the development of prototype drugs.
These contributions have been recognized through numerous awards including the National Science Foundation’s Career award in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011, and the Nancy Lurie Marks endowed professorship in 2015 and the Paul Marks Prize in 2019, and the Hope Funds for Cancer Research in 2023. -
Henry T. (Hank) Greely
Deane F. and Kate Edelman Johnson Professor of Law and, Professor, by courtesy, of Genetics
Current Research and Scholarly InterestsSince 1992 my work has concentrated on ethical, legal, and social issues in the biosciences. I am particularly active on issues arising from neuroscience, human genetics, and stem cell research, with cross-cutting interests in human research protections, human biological enhancement, and the future of human reproduction.
-
Sherril L. Green, DVM, PhD
Professor of Comparative Medicine, Emerita
Current Research and Scholarly InterestsResearch Interests: Xenopus laevis. Husbandry, biology, infectious and parasitic diseases of laboratory Xenopus laevis. Large animal models of disease.
-
Tamar Green
Associate Professor of Psychiatry and Behavioral Sciences (Interdisciplinary Brain Sciences) and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsThe Brain Imaging, Development, and Genetic (BRIDGE) Lab focuses on disorders associated with child development, such as attention deficits, hyperactivity, and autism spectrum disorders. we aim to uncover biological principles of how genetic variation and its associated downstream pathways affect children's neurodevelopmental disorders.
-
Harry B Greenberg
Joseph D. Grant Professor in the School of Medicine, Emeritus
Current Research and Scholarly InterestsMolecular mechanisms of pathogenesis; determinants of protective immunity; host range and tissue tropism in liver and GI tract pathogenic viruses and studies of vaccines in people.
-
Peter Greenberg
Professor of Medicine (Hematology), Emeritus
Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.
-
William Greenleaf
Professor of Genetics
Current Research and Scholarly InterestsOur lab focuses on developing methods to probe both the structure and function of molecules encoded by the genome, as well as the physical compaction and folding of the genome itself. Our efforts are split between building new tools to leverage the power of high-throughput sequencing technologies and cutting-edge optical microscopies, and bringing these technologies to bear against basic biological questions by linking DNA sequence, structure, and function.
-
Michael Greicius, MD, MPH
Iqbal Farrukh and Asad Jamal Professor and Professor, by courtesy, of Psychiatry and Behavioral Sciences (Administrative and Academic Special Programs)
Current Research and Scholarly InterestsAs the Founding Director of the Stanford Center for Memory Disorders and Principal Investigator of a lab focused on the genetics of Alzheimer's disease (AD), Dr. Greicius' research focuses on elucidating the neurobiologic underpinnings of AD. His lab combines cutting edge brain imaging, "deep" phenotyping, and whole-genome sequencing of human subjects to identify novel pathways involved in AD pathogenesis. The goal of his work is to develop effective treatment for AD patients.
